Adelmidrol: A novel osteogenic mineralization regulator for bone defect repair via activating the Notch pathway with drug-loaded hydrogel Authors: Fei Zhang, Fanchao Li, Chao Ren, ke Zhang, Hao Li, Hong Luo, Zhihong Xie, Kun Wei, Yang Liu, Yijie Zhang, Tao Wang, Wuxun Peng Published: 2026 ABSTRACT SummaryBone defect, irreversible bone loss impairing physiological functions, raises complication risks, lowers life quality and burdens healthcare, demanding effective novel repair strategies. This study aimed to screen candidate drugs promoting osteoblast (OB) osteogenic mineralization for bone defect repair. High-throughput screening identified adelmidrol from a phase 3 clinical drug library. In vitro experiments showed adelmidrol significantly upregulated RUNX2 and OSX expression, enhancing OB osteogenic mineralization by activating the Notch signaling pathway. In vivo, a methacrylated silk fibroin hydrogel scaffold loaded with aminated bioactive glass and adelmidrol (SFMA/GelMA/MBG-NH2-Ad) effectively promoted OB osteogenic mineralization, reduced bone defect area, and repaired mouse critical calvarial defects. In conclusion, this study clarifies adelmidrol’s regulatory effect on OB osteogenic mineralization and its molecular mechanism, confirms the scaffold’s efficacy in bone defect repair, providing a new candidate drug and experimental basis for clinical bone defect treatment.Keywords: osteoblasts, adelmidrol, osteogenic mineralization, Notch signaling pathway Introduction Bone tissue has multiple important functions in the human body, including support, protection, movement, and mineral storage. Bone defects or nonunion fractures caused by trauma, tumor resection, infection, degenerative diseases, and other factors exert a significant impact on patients’ quality of life and health.1,2,3 Although bone tissue possesses a certain degree of self-repair ability, natural repair often fails to restore the original structure and function of bones under conditions of severe injury or disease, thereby requiring clinical intervention.4,5 Clinical treatment methods for bone repair mainly include autologous transplantation, allogeneic transplantation, and internal fixation.6,7,8 Although these methods have been widely accepted, their shortcomings in clinical application are obvious—such as limited donor tissue, risk of infection during transplantation, potential immunogenicity, and other related issues.9,10,11,12 Therefore, how to effectively promote the repair and reconstruction of the body’s own bone tissue has become a major challenge in modern medicine. Osteoblasts (OBs) are the primary cell type in bone tissue, and they play an important role in the complex process of bone repair. By promoting the formation and continuous mineralization of the bone matrix, OBs gradually advance bone tissue reconstruction, ultimately achieving bone healing and functional recovery.13,14 Therefore, OBs are key cells for bone repair and indispensable participants in the bone regeneration process. However, during bone repair, changes in the local microenvironment—including alterations in the biochemical microenvironment, insufficient blood supply, bacterial infection, mechanical instability, and cell loss—lead to abnormalities in osteogenesis-related signaling pathways, such as Wnt/β-catenin, bone morphogenetic protein (BMP), and Notch.15,16,17,18,19,20 These abnormalities prevent OBs from performing normal mineralization and osteogenesis and hinder them from exerting their proper biological functions. Ultimately, this results in slowed bone healing, reduced bone quality, and even severe issues such as unhealable bone defects. Thus, exploring strategies to promote the osteogenic function of OBs is an effective approach to enhance the regenerative capacity of bone tissue. Drugs used to promote OBs differentiation and increase bone formation are limited, and they mainly include recombinant parathyroid hormone (PTH)-based drugs, strontium salts, fluorides, plant extracts, and natural products.21,22,23,24 Among these, fluorides, plant extracts, and natural products have not yet entered clinical use; the drugs that have been clinically applied are PTH-based drugs and strontium salts. PTH-based drugs, such as teriparatide, primarily activate PTH receptors to promote bone formation and increase bone mineral density, and they can also function by enhancing OBs proliferation and differentiation. However, their long-term use may lead to side effects such as hypercalcemia and an increased risk of osteosarcoma.25,26 Strontium ranelate is a clinically used strontium salt drug with dual effects of inhibiting bone resorption and promoting bone formation. Nevertheless, it mainly acts on osteoclasts, with negligible effects on OBs. Additionally, strontium ranelate increases the risk of deep vein thrombosis and may elevate the risk of adverse reactions in the cardiovascular system, thereby significantly limiting its clinical application.27,28 Although these drugs for promoting OBs osteogenic differentiation achieve a certain therapeutic effect, can exhibit significant side effects and may lack target specificity. Therefore, there is an urgent need to identify new compounds that are both safe and effective in enhancing OBs osteogenic function to improve the regenerative capacity of bone tissue. Candidate compounds in the phase 3 clinical drug library have mature safety evaluations, complete pharmacological data and clear clinical foundations, which can significantly shorten the research and development cycle and reduce risks of transforming basic research to clinical practice. By leveraging existing clinical trial data, they enable efficient discovery of active molecules with medicinal potential and transformation capabilities, providing reliable support for subsequent disease-targeted intervention and rapid clinical application. Based on the osteogenic phenotype of OBs, this project identified adelmidrol—a drug that promotes OBs osteogenic function—from a phase 3 clinical drug library via high-throughput drug screening technology. First, the effect of adelmidrol on OBs osteogenic function was investigated in vitro, and the mechanism by which adelmidrol enhances OBs osteogenic function was further explored. Finally, adelmidrol was loaded into a bioactive delivery hydrogel, and its role in repairing calvarial defects was verified using a calvarial-defect model. Results Based on the osteogenic phenotype, adelmidrol, a drug that promotes osteogenesis, was screened from the phase 3 clinical drug library OBs play an indispensable and crucial role in bone repair. To explore new osteogenic drugs that promote OBs function and to ensure the safety of newly discovered osteogenic drugs for earlier clinical application, we selected 532 compounds that have entered phase 3 clinical drug trials as the drug library. OBs were seeded in 24-well plates; and after adhering to the plates, they were induced to differentiate osteogenically for 21 days in the presence of 10 μM compound-containing induction medium. The effect of the drugs on OBs osteogenic function was detected by alizarin red quantitative assay (Figure 1A). The results showed that among the 532 compounds, 71 compounds had promotive effects on the osteogenic function of OBs. Among them, 34 compounds had a promotion ratio of at least 180%. The top five promotive compounds were spermidine, ralinepag, adelmidrol, casopitant mesylate, and apraglutide trifluoroacetate (TFA) (Figure 1B). Next, we conducted functional validation on the top five drugs with the highest promotion ratios. First, we tested the toxicity of these five drugs on OBs. The results showed that at a concentration of 10 μM, the drugs had no effect on the proliferation and apoptosis of OBs (Figures 1C–1E). Next, we used an induction medium containing 10 μM of the compounds to induce OBs mineralization into OBs. After 14 days of osteogenic induction, we detected the alkaline phosphatase (ALP) activity; and after 21 days, we detected the calcium salt content. The four compounds, namely spermidine, adelmidrol, casopitant mesylate, and apraglutide TFA, showed significant promotive effects on osteogenic mineralization. Spermidine and adelmidrol both showed osteogenic tissue specificity, and there was no difference in their promotive effects on osteogenic mineralization (Figures 1F–1I). Compared with spermidine, adelmidrol has lipophilicity and hydrophilicity and can better penetrate the cell membrane, thereby showing better bioavailability. Spermidine affects the detoxification function of the liver and increases the risk of cardiovascular diseases.29,30 Moreover, spermidine has been extensively studied in the field of orthopedics, so we chose adelmidrol as the candidate drug. Based on the osteogenic phenotype, adelmidrol, a drug that promotes osteogenesis, was screened from the phase 3 clinical drug library (A) Flowchart of drug screening. (B) Among 532 drugs, the top 5 phase 3 clinical drugs that enhance the osteogenic function of OBs are permidine, ralinepag, adelmidrol, casopitant mesylate, and apraglutide TFA. (C) CCK8 to detect the proliferation curve of OBs (n = 3). (D and E) Flow cytometry was used to detect the apoptosis rate of OBs and for the corresponding statistical analysis (n = 3). (F and G) ALP staining was used to detect the ALP activity in OBs and for quantitative analysis (n = 3). (H and I) ARS staining was used to detect the calcium crystal area in OBs and for quantitative analysis (n = 3). Error bars represent mean ± SD. Each experiment was conducted in biological triplicates for each condition. ns, not significant; p > 0.05, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Adelmidrol promotes the osteogenic mineralization function of OBs Based on the preliminary screening results, we further established an adelmidrol concentration gradient to verify the effects of different concentrations of adelmidrol on the OBs osteogenic mineralization function. We treated OBs with 0, 1, 5, 10, and 100 μM of adelmidrol and evaluated the effects of the different concentrations of adelmidrol on OBs activity, proliferation, and apoptosis. The results showed that at 24, 48, 72, and 96 h of the activity detection, none of the concentrations of adelmidrol had an effect on the activity of OBs (Figures 2A–2B and 2C). There was also no significant effect of the adelmidrol concentrations on the proliferation of OBs and their apoptosis rate (Figures 2D and 2E ). This indicated that adelmidrol had no effect on the activity, proliferation, and apoptosis of OBs within the above concentration range. Subsequently, we used osteogenic induction medium for OBs induction. The results showed that the alkaline phosphatase staining activity increased after adelmidrol treatment, and the calcium salt content also increased. The effect of the 10 μM concentration was the most significant; that is, the ALP staining was 0.68 times higher than that of the normal group (Figures 2F and 2G), and the calcium salt content was 1.34 times higher than that of the normal group (Figures 2H and 2I). Through western blot analysis, we found that the protein expression levels of osteogenic mineralization-related factors RUNX2 and Osterix (OSX) significantly increased after adelmidrol treatment. Specifically, in the 10 μM adelmidrol treatment group, the protein expression of RUNX2 and OSX increased by 5.30 and 0.96 times, respectively (Figures 2J–2L). In conclusion, adelmidrol can effectively promote the mineralization of OBs in vitro, and the effect at a concentration of 10 μM is the most significant. Adelmidrol promotes the osteogenic mineralization function of OBs (A and B) Calcein/phosphatidylinositol (PI) staining to detect the cell survival rate of OBs and for the corresponding statistical analysis (n = 3). (C and D) Flow cytometry was used to detect the apoptosis rate of OBs and for the corresponding statistical analysis (n = 3). (E) CCK8 to detect the proliferation curve of OBs (n = 3). (F and G) ALP staining was used to detect the ALP activity in OBs and for quantitative analysis (n = 3). (H and I) ARS staining was used to detect the calcium crystal area in OBs and for quantitative analysis (n = 3). (J–L) Western blot analysis was used to detect the relative expression of RUNX2 and OSX in OBs (n = 3). Error bars represent mean ± SD. Each experiment was conducted in biological triplicates for each condition. ns, not significant; p > 0.05, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Adelmidrol promotes the osteogenic mineralization function of OBs by activating the Notch signaling pathway In this study, we found that adelmidrol promoted the osteogenic mineralization function of OBs, but the specific regulatory mechanism remained unclear. By analyzing the molecular structure of Ademidrol and using the SwissTargetPrediction website to predict the proteins with which it might interact, a total of 61 proteins that could potentially interact with Ademidrol were ultimately identified. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis showed that the PI3K-protein kinase B(AKT)-mTOR and Notch signaling pathways were significantly enriched, which are related to the osteogenic mineralization of OBs (Figure 3A). To further verify the results of KEGG enrichment analysis, we observed that adelmidrol treatment did not affect the phosphorylation of PI3K and AKT and the expression of mTOR, indicating that adelmidrol cannot regulate the PI3K-AKT-mTOR signaling pathway. However, in the Notch signaling pathway, adelmidrol treatment increased the protein expression of Notch1, Notch intracellular domain (NICD), and Notch downstream target gene Hes1 (Figures 3B and 3C). Additionally, Notch1 mRNA, NICD1 mRNA, and Hes1 mRNA were all found to have increased levels, and the differences were statistically significant (Figure 3D). This suggests that adelmidrol may promote the osteogenic mineralization function of OBs by activating the Notch signaling pathway. Subsequently, on the basis of adelmidrol treatment of OBs, we applied the small-molecule inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) to inhibit the Notch signaling pathway. The results showed that after using the inhibitor, the expression levels of the key factors NICD1 and Hes1 in the Notch1 signaling pathway decreased, indicating that the activity of the Notch1 signaling pathway was effectively inhibited (Figures 3I and 3J). Both ALP staining and Alizarin Red staining (ARS) showed a decrease, and the levels of RUNX2 and OSX proteins also dropped. The promotive effect of adelmidrol on the osteogenic mineralization function of OBs was significantly weakened (Figures 3E–3J). These results indicate that adelmidrol promotes the mineralization function of OBs by activating the Notch signaling pathway. Adelmidrol promotes the osteogenic mineralization function of OBs by activating the Notch signaling pathway (A–C) GO analysis of predicted interacting proteins: biological process (BP), molecular function (MF), cellular component (CC). (A) KEGG analysis of predicted interacting proteins, where the PI3K-AKT-mTOR and Notch signaling pathways are related to bone formation. (B and C) Western blot detection of the relative expression of p-PI3K, t-PI3K, p-AKT, t-AKT, mTOR, Notch1, NICD1, and Hes1 (n = 3). (D) qPCR detection of the relative expression of Notch1 mRNA, NICD1 mRNA, and Hes1 mRNA (n = 3). (E and F) ALP staining was used to detect the ALP activity in OBs and for quantitative analysis (n = 3). (G and H) ARS staining was used to detect the calcium crystal area in OBs and for quantitative analysis (n = 3). (I and J) Western blot analysis was used to detect the relative expression of RUNX2, OSX, NICD1, and Hes1 in OBs (n = 3). Error bars represent mean ± SD. Each experiment was conducted in biological triplicates for each condition. ns, not significant; p > 0.05, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Preparation and characterization of SFMA/GelMA/MBG-NH2 with adelmidrol To investigate whether adelmidrol has the ability to repair bone defects in vivo, we constructed a silk fibroin methacrylylated (SFMA)/methacrylylated recombinant gelatin (GelMA)/mesoporous bioactive glass (MBG-NH2) hydrogel scaffold loaded with adelmidrol (SFMA/GelMA/MBG-NH2-Ad). Fourier transform infrared (FTIR) spectroscopy confirmed the synthesis of MBG-NH2-Ad (Figure 4A). Transmission electron microscopy (TEM) and laser nanoparticle size analysis showed that MBG was a mesoporous sphere and that the particle size of MBG-NH2 after amino modification increased. A large number of studies have confirmed that the material possesses the pore structure characteristics that are suitable for cell adhesion, infiltration and ingrowth.31,32 After loading adelmidrol, the spheres of MBG-NH2-Ad further increased, and adelmidrol particles were observed to be attached to the surface of MBG-NH2 (Figure 4B). Subsequently, FTIR spectroscopy confirmed the synthesis of SFMA and GelMA (Figure 4C), and 1H nuclear magnetic resonance (NMR) spectrum analysis confirmed the successful modification of SFMA and GelMA (Figure 4D). The rheological results analysis showed that after the hydrogel gelled, with the increase of time and shear frequency (Figures 4E and 4F), G′ of the SFMA/GelMA/MBG-NH2 mixture was always greater than G″ and there was no significant change (Figures 4G and 4H). This indicated that the hydrogel formed a stable three-dimensional network structure, thereby maintaining its gel state. The addition of MBG-NH2 significantly enhanced the elasticity and viscoelasticity of the hydrogel scaffold. Moreover, the addition of MBG-NH2 also improved the compressive strength of the hydrogel and reduced its swelling and degradation rates. The above results indicated that we successfully constructed the MBG-NH2-Ad/SFMA-GelMA hydrogel scaffold. Finally, we prepared different concentrations of adelmidrol aqueous solutions and measured their absorbance values to draw a standard curve, based on this calculation, the drug loading capacity of Adimiro in this composite hydrogel is determined to be 17.38% ± 0.26%. We also obtained the release curve of adelmidrol, which showed that approximately 29% of the drug was released in the first 3 days. The release rate of the drug gradually slowed down after that, reaching 50% of the cumulative release amount on the 14th day and approaching 90% of the cumulative release amount on the 37th day (Figures 4I–4L). This indicates that the hydrogel scaffold has excellent sustained-release performance. Preparation and characterization of SFMA/GelMA/MBG-NH2 with adelmidrol (A) FTIR infrared spectra of MBG, MBG-NH2, and MBG-NH2-Ad (n = 3). (B) TEM images and hydrated particle sizes of MBG, MBG-NH2, and MBG-NH2-Ad (n = 3). (C) Fourier transform infrared spectra of SF and SFMA (n = 3). (D) Fourier transform infrared spectra of Gel and GelMA (n = 3). (E and F) 1H NMR spectra of Gel, GelMA, SF, and SFMA (n = 3). (G and H) Relationship between the storage modulus, loss modulus, and time of the hydrogel (n = 3). (I) Full spectrum of the ultraviolet absorption peak of Adelmidrol (n = 3). (J and K) Standard curve and release curve of SFMA/GelMA/MBG-NH2-Ad (n = 3). Error bars represent mean ± SD. Each experiment was conducted in biological triplicates for each condition. ns, not significant; p > 0.05, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. SFMA/GelMA/MBG-NH2-Ad promotes the osteogenic mineralization function of OBs To verify the toxicity of SFMA/GelMA/MBG-NH2-Ad on OBs and its role in promoting bone mineralization, we conducted co-culture experiments with OBs and detected the survival status of OBs at different time points (24, 48, 72, and 96 h). The results showed that SFMA/GelMA/MBG-NH2-Ad had no significant effect on the proliferation and apoptosis of OBs, indicating that there was good biocompatibility between SFMA/GelMA/MBG-NH2-Ad and OBs (Figures 5A–5C). Based on the co-culture experiments, we further conducted osteogenic induction experiments. The results showed that the alkaline phosphatase staining in the SFMA/GelMA/MBG-NH2-Ad group was more obvious than that in the control group (Figures 5D and 5E), and calcium salt deposition was more abundant than that in the control group (Figures 5F and 5G). Moreover, the protein expression levels of RUNX2 and OSX significantly increased. Compared with the SFMA/GelMA/MBG-NH2 group, SFMA/GelMA/MBG-NH2-Ad had a stronger promotive effect on bone mineralization, with higher alkaline phosphatase staining activity and more calcium salt deposition. Western blot analysis also showed that the protein expression levels of RUNX2 and OSX further increased (Figures 5H–5J). In conclusion, SFMA/GelMA/MBG-NH2 can promote the mineralization process of OBs, while SFMA/GelMA/MBG-NH2-Ad shows a stronger ability to promote OB osteogenic mineralization. SFMA/GelMA/MBG-NH2-Ad promotes the osteogenic mineralization function of OBs (A and B) Cell survival rate and statistical analysis after co-culture of SGMA and OBs for 72 h (n = 3). (C) Proliferation curve of SGMA and OBs co-culture detected by CCK8 (n = 3). (D and E) ALP staining was used to detect the ALP activity in OBs and for quantitative analysis (n = 3). (F and G) ARS staining was used to detect the calcium crystal area in OBs and for quantitative analysis (n = 3). (H–J) Western blot analysis was used to detect the relative expression of RUNX2 and OSX in OBs (n = 3). Error bars represent mean ± SD. Each experiment was conducted in biological triplicates for each condition. ns, not significant; p > 0.05, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. SFMA/GelMA/MBG-NH2-Ad promotes the repair of critical cranial defects Next, we evaluated the efficacy of SFMA/GelMA/MBG-NH2-Ad in the repair of cranial bone defects in mice. The sample collection time was 6 weeks and 12 weeks after the cranial bone-defect modeling. At 6 weeks after operation, compared with the Sham group, the SFMA/GelMA/MBG-NH2 group showed a partial repair effect. In contrast, the SFMA/GelMA/MBG-NH2-Ad group demonstrated a better repair effect (Figure 6A). Hematoxylin and eosin (HE) staining results showed an increase in new bone tissue and a clear bone trabecular structure (Figure 6I). Masson staining results indicated a significant increase in blue collagen fiber deposition and active bone matrix synthesis (Figure 6J). Micro-computed tomography (CT) scan results showed an increase in bone volume (BV), bone surface area (BS), and bone volume fraction (BV/tissue volume [TV]) (Figures 6B–6D). Finally, immunohistochemical staining results indicated an upregulation of osteocalcin (OCN) expression level (Figure 6M). SFMA/GelMA/MBG-NH2-Ad promotes the repair of critical cranial defects (A) Micro-CT assessment of new bone formation in cranial defects in mice 6 weeks after surgery (n = 6). (B–D) Quantitative analysis of BV, BS, and BV/TV using micro-CT in mice 6 weeks after surgery (n = 6). (E) Micro-CT assessment of new bone formation in cranial defects in mice 12 weeks after surgery (n = 6). (F–H) Quantitative analysis of BV, BS, and BV/TV using micro-CT in mice 12 weeks after surgery (n = 6). (I) H&E staining results used to evaluate the morphological characteristics of bone tissue at the cranial defect site in mice (n = 6). (J) Masson’s trichrome staining results showing the bone tissue structure at the cranial defect site in mice (n = 6). (K and L) Osteo 680 detection of the fluorescence intensity at the cranial defect site in mice (n = 6). (M) IHC results showing the expression of OCN in the cranial defect area of mice. Sham, sham surgery group; SGM, SFMA/GelMA/MBG-NH2 group; SGMA, SFMA/GelMA/MBG-NH2-Ad group; PBS, phosphate-buffered saline; Osteo 680, IVISense Osteo 680 fluorescent probe. Error bars represent mean ± SD. Each experiment was conducted six times under each condition. ns, not significant; p > 0.05, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. At 12 weeks after operation, compared with the Sham group, the SFMA/GelMA/MBG-NH2 group showed certain repair effects, while the SFMA/GelMA/MBG-NH2-Ad group demonstrated more significant repair effects (Figure 6B). HE staining results showed a significant increase in the number of new bone tissues (Figure 6I), and Masson staining revealed a significant increase in the deposition of blue collagen fibers and active bone matrix synthesis (Figure 6J). Micro-CT results indicated that BV, BS, and BV/TV increased significantly (Figures 6B–6D). Additionally, we detected the fluorescence intensity at the mouse skull-defect site using the IVISense Osteo 680 Fluorescent Probe to reflect the amount of new bone formation in this area (Figure 6K). The results showed that the SFMA/GelMA/MBG-NH2-Ad group had more new bone formation than the SFMA/GelMA/MBG-NH2 group, and the SFMA/GelMA/MBG-NH2 group had more new bone formation than the Sham group. Moreover, immunohistochemical staining results showed an increased expression level of OCN (Figure 6M). These results indicate that SFMA/GelMA/MBG-NH2 promotes bone regeneration to a certain extent; and after loading adelmidrol, the bone regeneration effect is further strengthened, which is mainly attributed to adelmidrol’s good osteogenic mineralization effect. Discussion Through high-throughput drug screening, this study identified adelmidrol—a drug that promotes the osteogenic mineralization of OBs—from a phase 3 clinical drug library. In vitro experiments showed that adelmidrol increased the expression of RUNX2 and OSX in OBs, thereby enhancing the osteogenic mineralization function of OBs. Mechanistically, adelmidrol promoted the osteogenic mineralization function of OBs by activating the Notch signaling pathway. In vivo, the SFMA/GelMA/MBG-NH2-Ad hydrogel scaffold promoted the osteogenic mineralization of OBs, reduced the area of bone defects, and effectively repaired critical calvarial defects in mice (Figure 7). This study clarified the role and mechanism of adelmidrol in regulating the osteogenic mineralization function of OBs and provided a new and effective candidate drug for enhancing the osteogenic mineralization function of OBs. Adelmidrol promotes the repair of critical cranial defects by activating the Notch signaling pathway In vitro experiments showed that adelmidrol increased the expression of RUNX2 and OSX in OBs, thereby enhancing the osteogenic mineralization function of OBs. Mechanistically, adelmidrol promoted the osteogenic mineralization function of OBs by activating the Notch signaling pathway. In vivo, the SFMA/GelMA/MBG-NH2 loaded with adelmidrol promoted the osteogenic mineralization of OBs, reduced the area of bone defects, and effectively repaired critical calvarial defects in mice. Adelmidrol is an emerging bioactive molecule that has garnered attention primarily in pharmacological and biomedical research. Its chemical properties are similar to those of palmitoylethanolamide (PEA), an anti-inflammatory compound, with core functions including regulation of immune responses, exertion of antioxidant effects, and alleviation of inflammation.33,34 In previous studies, adelmidrol has demonstrated potential therapeutic effects on various diseases, such as allergic reactions, inflammatory bowel disease, osteoarthritis, and neurological disorders.35,36,37,38 However, no research has been conducted on the role of adelmidrol in the osteogenic mineralization of OBs. We found that adelmidrol significantly enhanced the osteogenic mineralization function of OBs in vitro. In vivo experiments confirmed that local release of adelmidrol notably increased the formation of new bone tissue and reduced the area of bone defects. Adelmidrol possesses prominent comprehensive advantages in osteogenic efficacy, targeted action mechanism, and clinical safety. It can effectively elevate bone mineral density, optimize bone microstructure, and improve bone mechanical properties, achieving more stable and sustained osteogenic regulation than PTH analogs, and effectively avoid adverse metabolic risks caused by long-term administration of PTH analogs. Mechanistically, adelmidrol specifically targets OBs and reduces non-specific off-target adverse reactions. In comparison, PTH analogs exert time-dependent bidirectional effects on bone metabolism, and long-term application is prone to metabolic imbalance; strontium salts simultaneously regulate both OBs and osteoclasts, lacking precise cell targeting ability. In terms of clinical safety, adelmidrol exhibits favorable biocompatibility with only occasional mild gastrointestinal reactions at a low incidence.39 It does not induce hypercalcemia risks triggered by PTH analogs, particularly in patients with renal dysfunction, nor does it correlate with the cardiovascular adverse events observed in strontium salt treatment. Overall, adelmidrol integrates reliable osteogenic performance, precise targeting characteristics, and high safety, holding great potential as a novel promising agent for clinical osteogenic mineralization therapy. The SFMA/GelMA/MBG-NH2 hydrogel is not only an ideal bone repair material but also a promising drug delivery system. Compared with conventional hydrogels, the composite hydrogel of SFMA and GelMA has superior biocompatibility, high mechanical strength, good elasticity, favorable bioactivity, and degradability.40,41,42,43 Methacrylation modification introduces methacryloyl groups, endowing it with photosensitivity for rapid photo-cross-linked gel formation.44 Aminated MBG-NH2 is further incorporated: bioactive glass (BG) promotes tissue-material chemical bonding, while amination enhances cell-material interaction for excellent biocompatibility. Its mesoporous structure provides a large surface area, facilitating drug loading and release.45,46 Upon contact with human body fluids, MBG-NH2 undergoes rapid ion exchange, forming a hydroxyapatite layer similar to bone tissue on its surface, which forms stable chemical bonds with bone and induces bone regeneration.47,48 The SFMA/GelMA/MBG-NH2 hydrogel enables targeted and sustained drug release, prolonging drug retention in damaged tissues and ensuring persistent biological effects, making it an integrated bone repair material with drug delivery function. Currently, hydrogels for wound dressings and drug carriers have entered clinical application; with interdisciplinary integration and innovation, more clinically valuable hydrogels will be developed to benefit medical advancement and human health. There is a close and complex regulatory relationship between the Notch signaling pathway and OB osteogenic mineralization, which plays an irreplaceable role in multiple stages of this process.49 For OBs, the directed differentiation of mesenchymal stem cells (MSCs) into OBs is the initial step of osteogenic mineralization, where the Notch signaling pathway exerts a key regulatory effect. Specifically, Notch receptor-ligand interaction triggers proteolytic events to release NCID, which activates target gene transcription.50,51 Previous studies have shown that Notch2 and Jagged1 (Jag-1) are involved in MSC differentiation into OBs, and Jag-1 can induce overexpression of the OB-related gene ALP, confirming the critical role of the Notch pathway in osteogenic differentiation.52,53 The Notch pathway also regulates OB maturation and function. Osteogenic mineralization relies on OB-derived bone matrix secretion and mineralization, which depends on the ordered expression of osteogenesis-related genes.54,55 Upon activation, Notch downstream target genes (e.g., HES/HEY family members) initiate cascade reactions, upregulating OB-specific markers such as ALP and OCN. As a key osteogenic enzyme, ALP provides phosphate ions for mineralization by hydrolyzing phosphates, while OCN participates in bone matrix mineralization and maturation; their upregulation directly promotes osteogenic mineralization.56,57 This study is the first to reveal that adelmidrol promotes OB osteogenic mineralization by activating the Notch signaling pathway. It provides new insights and a theoretical basis for bone regeneration and repair research, and potential new targets and strategies for treating related bone diseases. Through high-throughput compound screening technology, this study successfully identified adelmidrol—a candidate drug with a significant ability to promote osteogenic mineralization of OBs—from a phase 3 clinical drug library. Previous studies have shown that this drug can effectively enhance the osteogenic mineralization function of OBs by activating the Notch signaling pathway, thereby improving bone-forming capacity and achieving the repair of critical bone defects. Not only do these research results provide a new and effective drug target for regulating the osteogenic mineralization function of OBs, but they also clarify the molecular mechanism by which adelmidrol promotes osteogenic mineralization. They further offer a therapeutic regimen with translational potential for the clinical treatment of critical bone defects, demonstrating its important research value and application prospects in the field of bone tissue repair. Limitations of the study Although this study has achieved certain results, it still has limitations that need to be addressed and improved in future research. First, to verify the effect of adelmidrol on osteogenic mineralization, we conducted in vitro and in vivo studies using OBs and calvarial-defect models of C57 mice. However, due to significant differences in physiology, metabolism, and genomics between mice and humans, the experimental results may not be directly applicable to humans. Therefore, we plan to use large animal models in subsequent studies to validate the role of adelmidrol in osteogenic mineralization. Second, the potential target molecules on the surface of OBs are not unique to OBs; there is a phenomenon of “cross-expression,” which prevents the delivery system from accurately distinguishing OBs from other cells. This study only confirmed the necessity of the entire Notch pathway, but has not distinguished the precise regulatory sites of Ademidrol on Notch ligands (Jagged1/delta-like), receptor subtypes, and downstream Hes1/Hey1, and still lacks evidence of gene-specific intervention. Subsequently, the focus will be on conducting a systematic validation of the Wnt signaling pathway, delving deeply into the potential mechanism by which Adelmidrol mediates osteogenic differentiation through Notch/Wnt cross-regulation, and further improving the molecular mechanism research. Thus, improving the efficiency of the delivery system in accurately recognizing and binding to OBs is our next research goal. In summary, our experiment has certain limitations, and these limitations provide directions for improvement in subsequent studies. Resource availability Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Wuxun Peng (1536839333@qq.com). Materials availability This study did not generate new unique reagents. Data and code availability •This paper does not report original code. This paper does not report original code. •Our drug library consists of 532 compounds that have reached the stage of phase 3 clinical trials combined into an Excel file and are provided as supplemental information (Data S1). Our drug library consists of 532 compounds that have reached the stage of phase 3 clinical trials combined into an Excel file and are provided as supplemental information (Data S1). •The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request. The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request. Acknowledgments We thank the Clinical Medicine Research Center of The Affiliated Hospital of Guizhou Medical University and Laboratory of Emergency Medicine, The Affiliated Hospital of Guizhou Medical University for providing the experimental site and equipment. We thank LetPub (www.letpub.com.cn) for its linguistic assistance during the preparation of this manuscript. This work was supported by the National Natural Science Foundation of China (grant nos. 82560430, 82260429, 82260434, 82460426), Guizhou Provincial Basic Research Plan (natural science) talent team support project in 2025 (grant no. Qiankehe Basis QNB [2025] 006), The Eighth Batch of High-Level Innovative Talent Project in Guizhou Province (grant no. Qian Wei Ren Ling Ban Fa [2024] No. 3), Medical Research Union Fund for High-quality Health Development of Guizhou Province (grant no. 2024GZYXKYJJXM0129), Discipline Outstanding Reserve Talent Program of The Affiliated Hospital of Guizhou Medical University (grant no. gyfyxkrc-2023-07). Cultivation project of NSFC general program of The Affiliated Hospital of Guizhou Medical University (grant no. gyfynsfc[2023]-02), The Guizhou Provincial Basic Research Program (natural science) (grant no. Qiankehebasis-ZK [2025] general 455); The Youth Guidance Project of Basic Research Program of Guizhou Provincial Natural Science Foundation (grant no. Qiankehebasis-[2024] youth 251); The Science and Technology Foundation of Guizhou Provincial Health Committee (grant no. gzwkj2025-352); The start-up fund for doctoral research at The Affiliated Hospital of Guizhou Medical University (grant no. gyfybsky-2024-23). Guizhou Provincial Graduate Research Fund (grant no. 2025YJSKYJJ261). Guizhou Provincial Graduate Research Fund (grant no. 2025YJSKYJJ249) and the key advantageous discipline construction project of Guizhou Provincial Health Commission in 2024 in Emergency Department. Author contributions F.Z., F.L., C.R., and K.Z. designed the study, performed experiments, analyzed data, and wrote the manuscript; T.W. and W.P. designed the study and revised the manuscript; H. Li and H. Luo performed experiments and collected the data; Z.X. performed the experiments and provided technical assistance; K.W. and Y.L. helped with language editing. All authors reviewed the manuscript. Declaration of interests The authors declare no competing interests. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesanti-RUNX2 antibodyabcamCat#ab236639anti-OSX(Sp7/Osterix) antibodyabcamCat#ab209484anti-PI3K p110β antibodyProteintechCat#21739-1-APRRID:AB_1075537anti-phospho-PI3K p110α antibodyabcamCat#ab182651anti-total AKT antibodyProteintechCat# 10176-2-AP, RRID:AB_10636775anti-phospho-AKT (Ser473) antibodyProteintechCat# 66444-1-Ig, RRID:AB_2881241anti-mTOR antibodyAbcam,Cat# ab134903anti-Notch1 antibodyProteintech,Cat# 20687-1-AP, RRID:AB_10700012anti-Hes1 antibodyProteintechCat# 27542-1-AP, RRID:AB_2886970anti-OCN (Osteocalcin) antibodyAffinity BiosciencesCat# DF12303β-Actin AntibodyCell Signaling TechnologyCat#4967Goat Anti-Rabbit IgG (HRP)Cell Signaling TechnologyCat#7074Chemicals, peptides, and recombinant proteinsRIPA lysis bufferBeyotimeCat# P0013B,Fetal bovine serum (FBS),GibcoCat# 16000044Trizol reagentThermo15596018MEM α, nucleosidesGibco,Cat# 12571048,Critical commercial assaysAlkaline phosphatase (ALP) staining kitBeyotimeCat# C3206,Alizarin Red S (ARS) mineralized nodule staining kitCyagenCat# ALIR-10001Immunohistochemistry (IHC) staining kitBeyotimeCat# P0615IVISense Osteo 680 fluorescent probeRevvityCat# NEV10020EX,HE staining kitSolarbioCat# G1120Masson’s trichrome staining kitSolarbioCat# G1340Calcein/PI Cell Viability and Cytotoxicity Detection KitBeyotimeCat# C2015MCell Counting Kit-8BeyotimeCat# C0037Experimental models: Cell linesMC3T3-E1ATCCCat# CRL-2593,OligonucleotidesNotch1.Forward Primer:GGTGCCAACATCCGAGTCTAT,ReversePrimer:TCACACTCGTGTTGTTGATGGT;This paperN/ANICD1.Forward Primer:AATGAGTTCGTGAGTGGCTGT, Reverse Primer:GGTGATGGTGAAGGTGGTGTA;This paperN/AHes1.Forward Primer:CCAAGCTAGAGAAGGCCTTC, Reverse Primer:GGTGCTTCACAGTCATTTCCAThis paperN/ASoftware and algorithmsGraphPad PrismGraphPad SoftwareN/AImageJNational Institutes of HealthN/ASPSSIBMN/ASwissTargetPredictionhttps://www.swisstargetprediction.ch/N/AMestReNovahttps://www.mestrelabcn.com/N/ASkyScanhttps://www.bruker.comN/AOtherMicro-CTBrukerN/AUltraviolet spectrophotometerShimadzu CorporationUV1800Nuclear magnetic resonance spectrometerBrukerBruker-500Fourier transform infrared spectrometerBrukerVERTEX 70TEMHitachiH-800Nanoparticle size analyzerZeta Sizer Nano ZSN/AX-ray polycrystalline powder diffractometerSmartLab SEN/AECL luminescence kitPierceN/ANucleic acid protein analyzerNanodropND2000Flow cytometerBeckman CoulterN/AFluorescence microscopeCarl ZeissN/A Experimental model and study participant details Cell lines The MC3T3-E1 cells were purchased from Peiyou Biological Products Co., Ltd. in Guangzhou, China. Mycoplasma contamination testing was conducted biannually using a PCR-based detection method with the Universal Mycoplasma Detection Kit (ATCC 30-1012K). All cell lines tested negative for mycoplasma contamination throughout the study period. Cells were maintained in α-MEM medium (Merck) supplemented with 10% fetal bovine serum (Gibco, USA), 1% penicillin (100 U/mL), and 1% streptomycin (100 μg/mL) (Invitrogen, USA) at 37°C in a humidified atmosphere containing 5% CO2. Only cells within their first 20 passages were used for experiments to maintain consistent cellular characteristics. Animal models C57BL/6J mice, aged 3 months and weighing (20 ± 5) g, were provided by the Laboratory Animal Center of Guizhou Medical University. The mice were placed in individual ventilated cages under specific pathogen-free (SPF) conditions, with the temperature controlled at 22 ± 2°C and the humidity ranging from 50% to 60%. The animals had free access to standard laboratory feed and water that had been sterilized under high pressure. All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of Guizhou Medical University (approval ID: 2402798), following full ethical authorization from the university’s Experimental Animal Bioethics Committee (grant number 1900590). All laboratory animals were supplied by the Laboratory Animal Center of Guizhou Medical University (Guiyang, Guizhou, China). Every in vivo operation was performed strictly in line with the NIH Guidelines for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996). After the study, all animal remains were uniformly incinerated by the university’s Animal Experimental Center for standardized harmless disposal. Male mice were specifically selected to eliminate the potential influence of gender-related hormones on bone repair, as studies have shown that estrogen affects bone repair. In this research, gender was not considered as a confounding factor as a biological variable, and the focus was on the regulatory molecular mechanism of Adelmidrol on bone repair. In the experiment, the mice were randomly assigned to each experimental group (with 6 mice in each group), and their signs of stress were observed daily. After intraperitoneal injection of pentobarbital sodium (50 mg/kg) to anesthetize the mice, a 0.5-cm incision was made on the left scalp of the mouse’s skull to expose the skull. Then, a circular drill (diameter = 4 mm) was used to drill a 4-mm full-thickness skull-defect area. The skull-defect area was subsequently filled with hydrogel. The incision was sutured, and penicillin was continuously injected 3 days after the surgery to prevent infection. The mice were sacrificed at the 6th and 12th weeks after the surgery. Method details ALP staining After 14 days of osteogenic induction and differentiation of MC3T3-E1 cells, the cells were fixed with 4% paraformaldehyde for 15 min and washed three times with phosphate-buffered saline (PBS). The staining working solution was prepared in accordance with the instructions of the BCIP/NBT Alkaline Phosphatase Color Development Kit (Beyotime, China). An appropriate amount of the staining working solution was added to stain the cells, followed by incubation at room temperature in the dark for 30 min. The staining working solution was discarded, and the color development reaction was terminated by washing the cells twice with distilled water. The cells were then observed and photographed under a fluorescence microscope(Carl Zeiss, Oberkochen, Germany). Alizarin red staining (ARS) After 21 days of osteogenic induction and differentiation of MC3T3-E1 cells, the cells were fixed with 4% paraformaldehyde for 15 min and washed three times with PBS. An appropriate amount of alizarin red staining solution was added in accordance with the instructions of the Osteoblast Mineralized Nodule Staining Kit (OriCell, China). The solution was gently shaken to cover the cells, and staining was performed at room temperature for 30 min. Residual alizarin red staining solution was thoroughly removed by washing with PBS, and the cells were then observed and photographed under a microscope. After photography, PBS was discarded, and 1 mL of 10% cetylpyridinium chloride was added to each well to dissolve the calcium salts. A 500-μL aliquot of the dissolved solution was transferred to a 96-well plate, and the absorbance value at 562 nm was measured for quantitative analysis. Calcein/PI staining After MC3T3-E1 cells were treated, the supernatant was aspirated, and the cells were washed three times with PBS. The Calcein AM/PI detection working solution was prepared in line with the instructions of the Calcein/PI Cell Viability and Cytotoxicity Detection Kit (Beyotime, China). An appropriate amount of the staining working solution was added to stain the cells, followed by incubation at 37°C in the dark for 30 min. The cells were then observed and photographed under an inverted fluorescence microscope. Annexin V/PI staining After treatment of MC3T3-E1 cells, adherent cells were digested with trypsin without EDTA. The cell pellets were collected by centrifugation and then resuspended in 1× Binding Buffer. A 100-μL aliquot of the cell suspension was added to a 5-mL flow cytometry tube. Using the Annexin V-FITC Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA) in line with the manufacturer’s instructions, 5 μL of Annexin V-FITC and 5 μL of PI were added directly. The cells were gently vortexed and incubated at room temperature in the dark for 20 min. Subsequently, cell apoptosis was detected using a flow cytometer (Beckman Coulter, Indianapolis, IN, USA). CCK-8 assay A 96-well plate was used, with 2000 cells seeded per well. At the corresponding time points, CCK-8 working solution was added in accordance with the instructions of the Cell Counting Kit-8 (Beyotime, China), followed by incubation in a constant-temperature incubator for 2 h. The absorbance value (optical density, OD) was measured using a microplate reader at a wavelength of 450 nm. A cell proliferation curve was plotted based on the measured OD values. Western blot The total protein was extracted using RIPA lysis buffer, and the protein samples were quantified using BCA kit (Solarbio, China). SDS-PAGE gels were prepared. Equal amounts of denatured protein samples were subjected to electrophoresis. After the electrophoresis, the gels were cut, and the membranes were transferred on ice. The membranes were blocked with Quick Blocking Solution (EpiZyme, China) for 20 min. Anti-Osterix antibody (1:1000, ab209484, Abcam, UK), Anti-RUNX2 antibody (1:1000, ab236639, Abcam, UK), AKT antibody (1:1500, 10176-2-AP, Proteintech Group, China), Phospho-AKT (Ser473) antibody (1:1000, 66444-1-lg Proteintech Group, China), mTOR antibody (1:2000, ab134903 Abcam, UK), PI3K antibody (1;1000, 67071-1-lg Proteintech Group, China), Phospho-PI3K antibody (1:2000, ab182651 Abcam, UK), Notch1 Polyclonal antibody (1:1000, 20687-1-AP, Proteintech Group, China), Anti-Hes1 antibody (1;1200, 27542-1-AP, Proteintech Group, China), and β-Actin Antibody (1;6000, 4967, Cell Signaling Technology, USA) were used as primary antibodies at 4°C overnight, and HRP-linked anti-rabbit IgG (1:3000,7074,Cell Signaling Technology, USA) for 1 h at room temperature. Protein bands were visualized with the ECL luminescence kit (Pierce, Rockford, IL, USA), and images were acquired using a gel imaging system and analyzed using ImageJ (National Institutes of Health, Bethesda, MD, USA). Synthesis of methylacrylated SFMA Silkworm cocoons were boiled in 0.05 M sodium carbonate solution for 30 min, then rinsed and dried to obtain silk fibroin. The fibroin was mixed with sodium bicarbonate and lithium bromide solution, and dissolved under stirring at 60 °C for 4 h. Concentrated hydrochloric acid and glycidyl methacrylate were added sequentially, followed by 6-h reaction at room temperature. The mixture was dialyzed with a 1400-Da dialysis bag for 3–5 days, centrifuged at 5000 rpm for 10 min, and the supernatant was finally freeze-dried. Synthesis of methyl methacrylate gelling agent (GelMA) 5.0 g gelatin was fully dissolved in 50 mL PBS buffer via magnetic stirring at 50 °C water bath. Afterward, 3 mL methacrylic acid was added, and the mixture was stirred at 700 rpm for 1 h. The resultant solution was dialyzed in 40 °Cdeionized water for 3 days using a 3500 Da dialysis bag to eliminate impurities. After centrifugation at 5000 rpm for 10 min, the supernatant was collected and freeze-dried at −80 °C for 48 h to acquire GelMA. Preparation of aminated bioactive glass (MBG) containing adelmidrol 0.7 g CTAB was dissolved in 33 mL deionized water, followed by addition of 10 mL ethyl acetate and stirring for 30 min. After 7 mL ammonia water was introduced and stirred for 15 min, 3.6 mL TEOS and 0.36 mL triethyl phosphate were slowly added. Calcium nitrate tetrahydrate and extra deionized water were then supplemented, and the mixture was vigorously stirred at room temperature for 4 h.The solution was centrifuged to harvest white precipitates, which were rinsed and dried, then calcined at 600 °C for 5 h to obtain MBG. MBG was dispersed in anhydrous toluene and reacted with 3-aminopropyl triethoxysilane at 80 °C for 12 h to prepare aminated MBG-NH2.Adelmidrol aqueous solution was mixed with MBG-NH2, treated by ultrasonication and overnight stirring for sufficient drug adsorption. Finally, the mixture was centrifuged to separate unbound drug and solid sediment. Preparation of hydrogels We dissolved 2 mg of phenyl-2,4,6-trimethylbenzoylphosphonic acid lithium completely in 1 mL of deionized water. Then, we took 0.5 mL and dissolved 100 mg of GelMA at 40°C to obtain the GelMA solution. Next, we added 10 mg of drug-loaded bioactive glass and ultrasonically dispersed. We took 0.5 mL and dissolved 100 mg of SFMA at 4°C to obtain the SFMA solution. After mixing the GelMA and SFMA solutions, we exposed them to ultraviolet light at a wavelength of 365 nm for 2 min to crosslink and form a hydrogel scaffold. X-ray diffraction (XRD) After drying hydroxyapatite, it was ground in a agate mortar and then transferred to a test dish. The structure of the material was tested using an X-ray polycrystalline powder diffractometer (SmartLab SE, Rigaku, Japan). The instrument used a copper (Cu) target with K-rays, a wavelength of 1.5406 Å, a voltage of 40 kV, a current of 40 mA, and a scattering angle (2θ) ranging from 5° to 80°. Dynamic light scattering (DLS) A total of 1 mg of the sample to be tested was weighed separately, and it was ultrasonically dispersed in deionized water. The particle size and potential distribution were then detected using a nanoparticle size analyzer (Zeta Sizer Nano ZS, Malvern, UK). Transmission electron microscopy (TEM) We weighed 1 mg of the sample to be tested, dispersed it in deionized water, and performed ultrasonic dispersion. We used a 20-μL pipette to drop the solution onto a copper sheet, let it dry naturally, and then observed the morphology of the sample using a TEM (H-800, Hitachi, Japan). A 5 kV electron beam was used. Red color indication We took 5 mg of the sample to be tested, mixed it with 30 mg of dry potassium bromide powder, and ground them together. Then, we used the compression method to form a transparent thin sheet. The transmittance at 4000–400 cm−1 was detected using a Fourier transform infrared spectrometer (VERTEX 70, Bruker, Germany). Nuclear magnetic resonance characterization We weighed 8 mg of the sample to be tested, dissolved it in 600 μL of deuterated water, and placed in a clean nuclear magnetic tube. The nuclear magnetic structure was determined using a nuclear magnetic resonance spectrometer (Bruker-500, Bruker, Germany) at room temperature, and the spectra were analyzed using the MestReNova software. Rheological characterization of hydrogels Rheological measurements were conducted using a 25-mm diameter stainless steel parallel plate rotor (Kinexus Pro+, Malvern, UK). G′ represents the elastic modulus of the sample, while G″ represents the viscous modulus. The elastic modulus and viscous modulus were measured at a fixed strain of 1% for 5 min. At a fixed frequency of 1 Hz and a strain ranging from 0.1 to 10%, the elastic modulus and viscous modulus were measured. Compressive modulus 600 μL hydrogel was shaped into uniform cylinders with 11 mm base diameter. Samples were fixed on the universal testing machine (ELF3200, BOSE, USA), with fixtures closely attached to both hydrogel ends. Compression test was conducted at 0.05 mm/s until 70% strain. Pressure and displacement data were recorded. Compressive stress was calculated via the formula Compressive stress = F/S, where F represents pressure and S stands for hydrogel cross-sectional area. In vitro swelling of hydrogel 500 μL hydrogel precursor was added into each well of a 48-well plate and photocrosslinked. The obtained hydrogels were weighed to record initial mass W0. Samples were fully immersed in deionized water. Hydrogel weight Wt was measured at 1, 2, 4, 6, 8 and 12 h after wiping surface water. The swelling ratio was calculated using the formula: In vitro degradation of hydrogel 500 μL hydrogel precursor was added into 48-well plates and photocrosslinked. Samples were freeze-dried at −80 °C and weighed to record initial mass W0. Lyophilized hydrogels were immersed in PBS and incubated in a 37 °C shaker, with medium refreshed every three days. Specimens were harvested at 3, 7, 10, 14, 21 and 28 days, freeze-dried and weighed as Wt. The degradation rate was calculated as follows: Drug loading test of adelmidrol We dissolved 100 mg of adelmidrol in 1 mL of DMSO solution to prepare a 100 mg/mL solution. Then, we gradient-diluted it with pure water to 1000, 500, 250, 125, 62.5, and 31.125 μg/mL. We used an ultraviolet spectrophotometer (UV1800, Shimadzu, Japan) to measure the absorbance at 212 nm and drew a standard curve. We took the supernatant obtained after centrifugation after loading the drug as described in Section 1.3.5.1 and used the ultraviolet spectrophotometer to detect the absorbance at 212 nm. The content of the drug in the supernatant was calculated. In vitro drug release of adelmidrol 10 mg MBG-NH2-adelmidrol was ultrasonically blended with 1 mL SFMA/GelMA solution and photocrosslinked. The sample was immersed in 2 mL PBS buffer. 0.7 mL release medium was collected at preset time points and replenished with equal fresh PBS. Drug absorbance was measured via UV spectrophotometer. Corresponding concentration was calculated according to standard curve, and drug release profile was plotted.The formula for calculating the drug release amount is as follows: where Er is the cumulative drug release amount, Ve is the volume of each sampling (i.e., 0.7 mL), V0 is the total volume of the sustained-release liquid (i.e., 2 mL), Ci is the drug concentration measured during the i-th sampling, Cn is the drug concentration measured during the last sampling, and mdrug is the total mass of the drug. Hematoxylin and eosin (HE) staining At 6 and 12 weeks after the surgery, the mice were anesthetized and sacrificed. The skull specimens were collected. The specimens were fixed in 4% paraformaldehyde (Solarbio, China) for 1 day and then dehydrated for 2 weeks using EDTA decalcification solution. After dehydration, transparency, wax infiltration, embedding, sectioning, drying, and decalcification, the specimens were stained in line with the instructions of the HE staining kit (Solarbio, China), and microscopic photography and recording were conducted. Masson staining At 6 and 12 weeks after the operation, the mice were anesthetized and sacrificed. The skull specimens were collected. The specimens were fixed in 4% paraformaldehyde (Solarbio, China) for 1 day and then dehydrated for 2 weeks using EDTA decalcification solution. After dehydration, transparency, wax infiltration, embedding, sectioning, drying, and decalcification processes, the specimens were stained in line with the instructions of the Masson staining kit (Solarbio, China), and microscopic photography and recording were conducted. Immunohistochemical (IHC) staining After the mouse skull specimens underwent decalcification, fixation, dehydration, embedding, sectioning, dewaxing, hydration, and antigen retrieval, they were blocked with goat serum for 30 min. The OCN antibody (DF12303, Affinity Biosciences, China) was incubated at 4°C overnight. The biotinylated goat secondary antibody was incubated for 10 min. The chromogenic substrate DAB was added for color development, and hematoxylin was used for counterstaining. The slides were washed with warm water to reverse the blue color and then sealed with neutral gum. The specimens were examined under a microscope and photographed for record. Micro-CT analysis At 6 and 12 weeks after the operation, the mice were anesthetized and sacrificed. The skull specimens were collected and fixed in 4% paraformaldehyde for 1 day. The skull specimens were scanned using micro-CT (Bruker, USA) (X-ray tube voltage 55 kVp, X-ray tube current 500 μA, resolution 10.4 μm). The skull images were reconstructed using image reconstruction software (SkyScan, USA), and BV, BS, and BV/TV of the newly formed bone in the bone defect area were measured using a unified threshold. Osteo 680 fluorescent probe analysis Two days before the sacrifice of the mice, 100 μL of IVISense Osteo 680 Fluorescent Probe(IVISense Osteo 680 Fluorescent Probe, trade name OsteoSense 680EX) Supplier: Revvity) Catalog Number (Lot Number): NEV10020EX. was injected via the tail vein, at a concentration of 2 nmol/100 μL. Twelve hours and 24 h after the injection, the fluorescence intensity in the skull-defect area was observed and recorded using the small-animal imaging instrument (Bruker, Germany). Quantification and statistical analysis All experiments were conducted independently at least three times (in vitro studies involved 3 biological replicate samples, and in vivo experiments involved 6 mice), unless otherwise specified. Statistical significance between groups was determined using GraphPad Prism 9.0 and SPSS 23.0 software packages.For comparisons between two groups,a two-tailed Student’s t test was applied. For comparisons involving more than two groups, Analysis of Variance (ANOVA) was utilized. All quantitative data are presented as the mean ± standard deviation (SD). The significance level for all analyses was consistently set at p < 0.05. All specific statistical details, including statistical tests used, exact value of n, what n represents, definition of center, and dispersion and precision measures, are provided in the corresponding figure legends, figures, and the results section of the manuscript. Footnotes Supplemental information can be found online at https://doi.org/10.1016/j.isci.2026.116941. Contributor Information Tao Wang, Email: 1911095370@qq.com. Wuxun Peng, Email: 1536839333@qq.com. Supplemental information Data S1. 532 kinds of phase 3 clinical compounds were quantitatively evaluated for their effects on osteoblast osteogenic function using Alizarin Red., related to Figure 1A References Associated Data Supplementary Materials Data S1. 532 kinds of phase 3 clinical compounds were quantitatively evaluated for their effects on osteoblast osteogenic function using Alizarin Red., related to Figure 1A Data Availability Statement •This paper does not report original code. This paper does not report original code. •Our drug library consists of 532 compounds that have reached the stage of phase 3 clinical trials combined into an Excel file and are provided as supplemental information (Data S1). Our drug library consists of 532 compounds that have reached the stage of phase 3 clinical trials combined into an Excel file and are provided as supplemental information (Data S1). •The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request. The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request.